Baxter completes acquisition of Claris Injectables

Baxter has expanded its generic injectable medicines portfolio with the completion of its takeover of Claris Injectables.

This takeover gives Baxter access to the complete Claris Injectables product portfolio and pipeline, as well as three manufacturing plants that feature state-of-the-art technology and are fully registered with global regulatory agencies.

In the coming years, Baxter will invest in further increasing Claris Injectables' capacity and capabilities by adding new aseptic manufacturing and lyophilisation, new technology platforms in areas like cytotoxics, aseptic development and complex formulations, and an expanded research and development footprint.

Overall, the acquisition is expected to add more than 50 products to Baxter's portfolio in 2017, almost 20 new products in the aggregate in 2018 and 2019, and ten to 15 products per year beginning in 2020.

Jose Almeida, chairman and chief executive officer at Baxter, said: "The combination of Baxter and Claris Injectables will allow us to increase access to lower-cost generic injectables and strengthen our ability to meet the needs of healthcare providers and patients around the world."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.